Fig. 1. Glycemic variability in three hypothetical patients who have the same mean blood glucose concentration. Patient B has relatively small variations.

Slides:

Advertisements

Similar presentations

Figure 1.1 The observer in the truck sees the ball move in a vertical path when thrown upward. (b) The Earth observer views the path of the ball as a parabola.

Advertisements

 insulin and glucagon- Which regulate the level of glucose in the blood  Somatostatin- which prevents the release of the insulin and glucagon.

A Day in the Life of a Type 2 Diabetic

New Insulin Formulations

Rachel Whittle Undergraduate ( Health Science Concentration) Department of Biology Tennessee Tech University Cookeville, TN Influence Diet and Exercise.

October 22, 2012 GHA- Glycemic Management Collaborative.

Hypoglycemia & Hyperglycemia Dave Joffe, BSPharm, CDE, FACA.

Pattern Recognition Ver D/sv/ What Is Pattern Management ? A systematic approach to making effective use of SMBG data. – Establishing pre-

Mastery of Medicine in Diabetes Management Video Roundtable

Clinical usefulness of measuring urinary polyol excretion by gas-chromatography/mass- spectrometry in type 2 diabetes to assess polyol pathway activity

Insulin Degludec Drugbank ID :DB09564

Use of Insulin Pump in Children with Type I Diabetes Mellitus: Effect on glycemic control and Body Mass Indices (BMI). Noura Al Hemaidi, Maryam Al Ali,

Volume 64, Issue 4, Pages (October 2003)

Robert Vigersky, Maneesh Shrivastav

Copyright © 2006 American Medical Association. All rights reserved.

Copyright © 2004 American Medical Association. All rights reserved.

Fig. 1. Scheme of the evaluation protocol

From: United Kingdom Prospective Diabetes Study 17: A 9-Year Update of a Randomized, Controlled Trial on the Effect of Improved Metabolic Control on Complications.

*** *** *** *** *** *** Supplemental Fig. 1 A B N = 27 N = 15

Online Gifts Buy for wishes happy mother's day to yours choice and with happy gifts find here:

Diabetes and Risk of CV Outcomes

Components of a CGM record over a 3

Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.

Using the AGP to Standardize Glucose Reporting

New Patient-Friendly Options for Managing Insulin Dosing

Cardiovascular (CV) Safety and Severe Hypoglycemia Benefit of Insulin Degludec vs Insulin Glargine U100 in Older Patients (≥65 years) with Type 2 Diabetes.

Best Practices in Advanced Glucose Monitoring

Diabetes Journal Club Julie Shah.

Updates to Managing Diabetes in the Long-Term Care Setting

A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.

Rank-order bar chart of percentage of patient-days with blood glucose results > 299 mg/dl for non-ICU units. Rank-order bar chart of percentage of patient-days.

Integrated Diabetes Care: How Can We Make the Best Use of New Technology?

Dependent v. Independent Variables

George Dailey, MD Mayo Clinic Proceedings

The Research Question Does self monitoring of blood glucose (SMBG) in patients with non-insulin treated type 2 diabetes improve glycemia or quality of.

Effects of highly concentrated SFN provided as BSE in T2D patients

GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?

Better Diabetes Control With Novel Basal Insulins

Severe hypoglycemia after initiation of anti–tumor necrosis factor therapy with etanercept in a patient with generalized pustular psoriasis and type 2.

Fig. 2. Calculation of mean amplitude of glucose excursion (MAGE)

Modern Advances in Glucose Monitoring

Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?

Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.

Dual SGLT1/SGLT2 Inhibition in T1D

Hypoglycemia: The Most Common Barrier to Effective Diabetes Management

Fig Reduced beta cell mass in type 2 diabetic patients, as compared to non-diabetic controls, although there is a marked inter-subject variability.

Glucose Control Lowers the Risk of Wound Infection in Diabetics After Open Heart Operations Kathryn J Zerr, MBA, Anthony P Furnary, MD, Gary L Grunkemeier,

Managing Hypoglycemia & Hyperglycemia

Volume 64, Issue 4, Pages (October 2003)

Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodeficiency: Clinical and immunologic outcomes.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Fig. 2. B1-inhomogeneity-induced variation of pre-contrast R1 in gray matter (reference value, sec-1) and blood (reference value, sec-1). A.

Strict glycemic control reduces EuroSCORE expected mortality in diabetic patients undergoing myocardial revascularization Cosimo D’Alessandro, MD, Pascal.

One- to two-hour plasma glucose concentrations over a 24-hour period in patients taking maximal doses of either glyburide (20 mg/day) or glipizide (40.

Fig. 3. (A) Least-squares (LS) mean difference in glycosylated hemoglobin (HbA1c) from baseline, and (B) LS mean difference in HbA1c from baseline over.

GLP-1 and gastrin combination therapy restores normoglycemia in NOD mice. GLP-1 and gastrin combination therapy restores normoglycemia in NOD mice. Beginning.

Subchronic glycemic effects after vehicle, metformin, SGLT2I, or combination treatment. Subchronic glycemic effects after vehicle, metformin, SGLT2I, or.

Blood glucose levels in chicken embryos.

Proportion of patients experiencing documented symptomatic hypoglycemia (blood glucose

Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

Postoperative blood glucose levels and total insulin requirement.

Effects of highly concentrated SFN provided as BSE in T2D patients

Distribution of blood glucose levels by screening test in patients with diabetes and patients without diabetes; to convert mg/100 ml to mmol/l multiply.

Elevated blood glucose vs time.

Novel presentation of glucose data from a patient with type 1 diabetes

A: Glucose levels during basal-bolus and SSI treatment.

Fig. 1. The composite analysis of the risk of major adverse cardiovascular events (MACEs) from three cardiovascular outcome trials, expressed as relative.

ERRs (degludec/glargine U100) of hypoglycemia in Hispanic and non-Hispanic patients during the SWITCH 2 trial. ERRs (degludec/glargine U100) of hypoglycemia.

Benchmarking scatterplot for non-ICU units.

Presentation transcript:

Fig. 1. Glycemic variability in three hypothetical patients who have the same mean blood glucose concentration. Patient B has relatively small variations during the day and on different days; this patient should have little difficulty in lowering daily mean blood glucose concentrations without inducing hypoglycemia. In comparison, patient A has marked blood glucose variations on the same day and patient C has marked blood glucose variations on different days. Fig. 1. Glycemic variability in three hypothetical patients who have the same mean blood glucose concentration. Patient B has relatively small variations during the day and on different days; this patient should have little difficulty in lowering daily mean blood glucose concentrations without inducing hypoglycemia. In comparison, patient A has marked blood glucose variations on . . . Diabetes Metab J. 2015 Aug;39(4):273-282. http://dx.doi.org/10.4093/dmj.2015.39.4.273